Navigation Links
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Date:1/25/2010

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm

QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals ( KERX), presented updated results yesterday on the clinical activity of perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda(R)) as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, "Randomized Phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results", was presented yesterday in a poster during the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in Orlando, Florida. Keryx is Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while Æterna Zentaris retains rights for the rest of the world.

Study Design

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colon cancer were randomized to receive cape
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Envera announced ... Fermentation Manager. Mr. McErlean has an extensive background ... leadership positions throughout his career. , Mike ... very pleased to have Mike join our team”. “Mike’s ... large scale fermentation and downstream processing equipment”, ...
(Date:5/21/2013)... , May 22, 2013 First ... formulation of glycopyrronium bromide designed using Prosonix, particle engineering ... developing a portfolio of inhaled Respiratory Medicines by ... with PSX1002 that will assess its effect on lung ... in patients with moderate to severe chronic obstructive pulmonary ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... the Anniversary by Ringing The Closing Bell(R) at ... the ... Edwards,Lifesciences Corporation (NYSE: EW ), a world leader in ... of partnering with clinicians to develop life-saving,innovations. To celebrate its five ...
... Anadys,Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Conference on Wednesday, April 9, 2008,at 3:00 p.m. EDT ... the St.,Regis Hotel in New York City., Steve ... Inc., will present an overview of Anadys and an ...
... 2, 2008 BioSpace, the world,s,leading online bioscience job ... Bio NC(TM) Career Fair on Thursday, May 1, 2008. ... from 11 am to 4 pm., (Logo: ... North Carolina will attend the,biotech job fair to meet ...
Cached Biology Technology:Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference 2Bioscience Career Fair in North Carolina Expected to Attract Well Qualified Job Seekers 2
(Date:5/22/2013)... of potential environmental and human health effects from ... year has led scientists to recommend stronger government ... lithium-ion (Li-ion) battery materials. That,s the conclusion of ... Environmental Science & Technology . , Oladele A. ... have become mainstays for powering everything from smart ...
(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...
(Date:5/21/2013)... device attached to a whale entangled in fishing gear, ... changed a whale,s diving and swimming behavior. The monitoring ... and migrate, depletes their energy as they drag gear ... slow death. , The scientists in this entanglement response ... two-year-old female North Atlantic right whale called Eg 3911. ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... American Society for Biochemistry and Molecular Biology expressed its ... Aug. 23 ruling in the U.S. District Court for ... barring federal funding of embryonic stem-cell research. In ... in response to a lawsuit filed by two adult ...
... Scripps Research Institute scientists have identified two proteins with potential ... of health problems, including pain, deafness, and cardiac and kidney ... Express, the advanced, online edition of the journal Science, on ... Research scientists identify two proteins, which they named Piezo1 and ...
... New Orleans, LA In a first person paper ... Obesity, Dr. Melinda Sothern, Director of Health Promotion and ... New Orleans, provides three ways to de-program the 1950s ... United States and protect future generations from its health ...
Cached Biology News:American Society for Biochemistry and Molecular Biology reacts to stem-cell ruling 2Scientists identify molecules involved in touch and other mechanically activated systems 2Scientists identify molecules involved in touch and other mechanically activated systems 3Scientists identify molecules involved in touch and other mechanically activated systems 4LSUHSC pediatric weight expert provides obesity trinity answers 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
... molecular screening, low melting point agarose where ... is recommended for separation of nucleic acids ... PCR products. Micro ABgarose is also suited ... for blotting techniques. At a 3% concentration, ...
Biology Products: